Aurinia Pharmaceuticals Inc. (AUPH)

Market Cap	1.29B
Revenue (ttm)	220.36M
Net Income (ttm)	-22.55M
Shares Out	143.18M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	24.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,409,769
Open	8.95
Previous Close	9.04
Day's Range	8.92 - 9.23
52-Week Range	4.71 - 10.67
Beta	1.26
Analysts	Strong Buy
Price Target	10.33 (+14.4%)
Earnings Date	Feb 13, 2025

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 1999
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: AUPH
• Website: https://www.auriniapharma.com

Financial Performance

In 2023, Aurinia Pharmaceuticals's revenue was $175.51 million, an increase of 30.95% compared to the previous year's $134.03 million. Losses were -$78.02 million, -27.88% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is $10.33, which is an increase of 14.40% from the latest price.

Price Target

$10.33

(14.40% upside)

Analyst Consensus: Strong Buy